Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/25/2025

Beyfortus (Nirsevimab) Pharmacology and Clinical Guidelines

Introduction to Beyfortus

  • The American Academy of Pediatrics recommends Beyfortus (nirsevimab) as a single intramuscular injection shortly before or during the RSV season for all infants aged <8 months who are born during or entering their first RSV season 1, 2

Dosing and Administration

  • The Centers for Disease Control and Prevention recommends administering Beyfortus as a single intramuscular injection shortly before or during the RSV season (typically fall through spring) for infants aged <8 months who are born during or entering their first RSV season, and also for infants and children aged 8–19 months who are at increased risk for severe RSV disease and are entering their second RSV season 1, 2

Special Populations

  • High-risk populations for second-season dosing of Beyfortus include children with chronic lung disease of prematurity requiring medical support, children with severe immunocompromise, children with cystic fibrosis with severe lung disease or poor growth, and American Indian or Alaska Native children 3, 4

Safety and Contraindications

  • The FDA recommends that Beyfortus is contraindicated in persons with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose or product component 4, 5

Adverse Event Reporting

  • Adverse events should be reported to FDA MedWatch or to VAERS if co-administered with vaccines, as recommended by the Centers for Disease Control and Prevention 3, 5

Comparison to Previous Prophylaxis

  • Unlike palivizumab, Beyfortus requires only a single dose for the entire RSV season rather than monthly injections, as noted by the American Academy of Pediatrics 6

RSV Prophylaxis in Pediatric Populations

FDA-Approved Indications and Contraindications

  • The Centers for Disease Control and Prevention recommends nirsevimab for infants <8 months born during or entering their first RSV season, and for a subset of high-risk children aged 8-19 months entering their second RSV season 7
  • The FDA has not approved nirsevimab for use in adult populations, as no safety or efficacy data supports its use in this group 7, 8

Potential Risks and Contraindications

  • The American Academy of Pediatrics notes that severe allergic reactions, including anaphylaxis, are contraindicated in anyone with prior hypersensitivity to nirsevimab or its components 7
  • Bleeding complications could theoretically occur in patients with bleeding disorders, and special precautions are recommended 7, 9

REFERENCES